Lv1
30 积分 2025-01-07 加入
63P FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only (LL), right-sided and/or RAS or BRAF mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials
1天前
已完结
Preoperative chemotherapy prior to primary tumor resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: A multicenter randomized controlled trial
1天前
待确认
皖公网安备34019202002308
